Theravance plans 50% workforce cut as strategic review weighs sale About 50% of jobs are set to be cut, with $5M-$7M in severance. The overhaul aims to trim expenses 60%, with full savings expected in Q3 2026.

#TBPH Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/TBPH/theravance-bio...

Theravance Biopharma Faces Shareholder Disappointment Amid Trial Failures and High Operating Costs Theravance Biopharma's recent Phase 3 trial failure and $22M in operating expenses have left investors reeling. Shareholders lost 26% due to the disappointing news.

Theravance Biopharma Faces Shareholder Disappointment Amid Trial Failures and High Operating Costs #None #Theravance_Biopharma #TBPH #CYPRESS_trial

Crude Oil Surges Over 6%; Target Profit Tops Views - Battalion Oil (AMEX:BATL), Kontoor Brands (NYSE:KTB) US stocks down amid Iran-US conflict. Tehran closed Strait of Hormuz & warned of firing on vessels. Dow down 2.45%, NASDAQ down 2.62%, S&P; 500 down 2.34%.

Crude Oil Surges Over 6%; Target Profit Tops Views US stocks down amid Iran-US conflict. Tehran closed Strait of Hormuz & warned of firing on vessels. Dow down 2.45%, NASDAQ down 2.62%, S&P...

#BATL #Equities #KTB #MAIA #Mid-Day #Market #Update #News #PSIX #TBPH #TGT

Origin | Interest | Match

Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions Theravance Biopharma (NASDAQ: TBPH) reported that the Phase 3 CYPRESS study of ampreloxetine did not meet the primary OHSA composite endpoint, and the company will wind down the program. The Board's Strategic Review Committee is accelerating a review of alternatives, including a potential sale. The company is restructuring to cut operating expenses ~60% (≈$70M run-rate), expect ~50% workforce reduction, and forecasts $60–$70M annualized cash flow starting Q3 2026. Cash was $326.5M at 12/31/2025; approximately $400M expected EoQ1 2026, and a $100M TRELEGY milestone is expected in 2026.

#TBPH Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions

www.stocktitan.net/news/TBPH/theravance-bio...

Irenic Dumps Most Papa John's Shares | The Motley Fool Papa John's International runs a global pizza network, earning revenue from both direct restaurant operations and franchise royalties.

#PZZA #ITGR #SHC #TBPH #ALKT #WK #c903f364-9dcf-45f7-9cfa-c7044f776c0e #coveragefilings

Origin | Interest | Match

Trade Alerts, Wednesday January 14, 2026 – Crystal Equity Research

Small-cap stocks with improving money flow, Wed Jan 14th - #XOMA #WBTN #TBPH #SABS #ACHV #BOOM #CHCO #FOSL #GNPX #IMCC #KXIN #MAZE #NEWT #ORMP #UA #RYAM #PKST #NGVC #LXFR #GCO #FCRS #DCO #CC #ADNT - More: crystalequityresearch.com/trade-alerts... - #smallcap

Theravance Biopharma to Engage in Investor Conferences This December Theravance Biopharma will participate in significant investor conferences in December 2025, showcasing industry leadership and innovations.

Theravance Biopharma to Engage in Investor Conferences This December #None #YUPELRI #Theravance #TBPH

Theravance Biopharma Launches Disease Education Campaign to Advance Scientific Understanding of Neurogenic Orthostatic Hypotension Due to Multiple System Atrophy Theravance Biopharma (NASDAQ: TBPH) launched “Power in the Periphery,” a disease education campaign for healthcare professionals to raise awareness of neurogenic orthostatic hypotension (nOH) in Multiple System Atrophy (MSA).The initiative was introduced at the International Congress of Parkinson’s Disease and Movement Disorders (MDS) in Honolulu, October 5–9, 2025, and aims to deepen scientific understanding of nOH pathophysiology in MSA and improve clinician engagement. nOH symptoms include lightheadedness, fainting, fatigue, blurry vision, weakness, concentration problems, and head/neck pain. Theravance directs clinicians to www.nOHUncovered.com for educational resources.

#TBPH Theravance Biopharma Launches Disease Education Campaign to Advance Scientific Understanding of Neurogenic Orthostatic Hypotension Due to Multiple System Atrophy

www.stocktitan.net/news/TBPH/theravance-bio...

Theravance Sales Jump 83 Percent | The Motley Fool

#TBPH #1cdeb438-78da-4722-af57-9b45d4ca4b93 #data-news

Origin | Interest | Match

Breakthrough COPD Treatment: China Approves First-Ever Once-Daily Nebulized YUPELRI, Triggers $7.5M Milestone China's NMPA approves groundbreaking once-daily COPD treatment. Unlock details about $7.5M milestone payment and future revenue potential. See market impact.

#TBPH Theravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China's NMPA

www.stocktitan.net/news/TBPH/theravance-bio...

Theravance Cashes Out Trelegy Royalties: $225M Deal Unlocks $1.5B Total Value from GSK Just announced: $225M cash deal plus retained $150M milestone rights. See how this strategic sale fits into Theravance's $1.5B total Trelegy monetization plan. Get details.

#TBPH #GSK Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million

www.stocktitan.net/news/TBPH/theravance-bio...

Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress Theravance Biopharma (NASDAQ: TBPH) presented analyses of its Phase 3 program for ampreloxetine, a treatment for symptomatic neurogenic orthostatic hypotension (nOH), at the International MSA Congress. The subgroup analysis from the REDWOOD 0170 study showed that Multiple System Atrophy (MSA) patients experienced meaningful improvement in nOH symptoms after 16 weeks of treatment, with symptoms remaining stable in the ampreloxetine group while worsening in the placebo group.Key findings revealed improved functional activities in treated patients and demonstrated ampreloxetine's sustained effect on standing blood pressure. Additional analysis from Study 0169 highlighted that MSA patients had the highest nOH symptom burden despite existing treatments, emphasizing the need for better therapies. These results support the ongoing CYPRESS registrational study in nOH and MSA patients.

#TBPH Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress

www.stocktitan.net/news/TBPH/theravance-bio...

Theravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update Theravance Biopharma (TBPH) reported its Q1 2025 financial results, highlighting strong performance across key products. YUPELRI achieved US net sales of $58.3 million, up 6% year-over-year, with notable 48% growth in hospital channel doses. TRELEGY posted global net sales of $854 million, representing a 14% increase from Q1 2024.The company reported total revenue of $15.4 million and a net loss of $13.6 million. Quarter-end cash balance stood at $130.9 million with no debt. R&D expenses were $11.5 million, while SG&A expenses reached $18.4 million.The CYPRESS study for ampreloxetine, targeting neurogenic orthostatic hypotension in MSA patients, is nearing completion with final patient enrollment expected by late summer. The company's Strategic Review Committee continues to evaluate alternatives to enhance shareholder value.

#TBPH Theravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/TBPH/theravance-bio...

don't ask me why i'm so behind on outfit updates, i was mainlining the HR story because i want it to be over #tbph

Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results Theravance Biopharma (TBPH) reported strong Q4 and FY 2024 results, with YUPELRI achieving record US net sales of $66.7M in Q4 (up 10% YoY) and $238.6M for FY2024 (up 8% YoY). TRELEGY global net sales reached $3.46B in FY2024, up 26% YoY, triggering a $50M milestone payment to TBPH.Q4 financial highlights include revenue of $18.8M from Viatris collaboration, R&D expenses of $9.5M, and SG&A expenses of $18.5M. The company ended Q4 with $88.4M in cash, excluding the $50M TRELEGY milestone received in February 2025.For 2025 guidance, TBPH expects R&D expenses of $32-38M and SG&A expenses of $50-60M (excluding share-based compensation). The CYPRESS study for ampreloxetine remains on track to enroll its final patient by mid-2025.

#TBPH Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results

www.stocktitan.net/news/TBPH/theravance-bio...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with bearish crossover of moving average convergence divergence signal, Mon Feb 10th - #XPEL #WPRT #UFPT #TBPH #SEVN #RZLT #PCRX #OCCI #MERC #JRVR #HRTX #ELTX #DCTH #CCSI #BDTX #UNFI #SMWB #GGT #DHT - More: crystalequityresearch.com/SmCpStr/ - #smallcap

#TBPH Theravance Biopharma to Participate in an Upcoming Investor Conference

www.stocktitan.net/news/TBPH/theravance-bio...

BREAKING NEWS: ( NASDAQ: #TBPH ) Theravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024

#StockMarket #News

NEWS: ( NASDAQ: #TBPH ) How To Trade (TBPH)

#StockMarket #News

BREAKING NEWS: ( NASDAQ: #TBPH ) Theravance Biopharma to Report Second Quarter 2024 Financial Results on August 5, 2024

#StockMarket #News

ich fang ja in frühestens 2 Stunden an. Der Mangel an Zuhörern tangiert mich im Moment gar nicht. aber später würde er das auch nicht. #tbph